• Ayleen Rivera-Tenorio, Héctor Hernández Díaz, Pablo Andrés Triana, Juliana Gutiérrez-Posso, Ana María Osorio-Gómez, Julio Ernesto Saez Velandia, William Salazar Acosta, and José Darío Portillo-Miño.
• Especialización en Medicina Interna, Departmento de Medicina Interna, Facultad Ciencias de la Salud, Universidad Libre, Cali. Colombia.
• Colomb Medica. 2022 Jul 1; 53 (3): e5005187e5005187.

Case DescriptionA 22-year-old female patient received the first dose of Pfizer-BioNTech vaccine (RNAm) against COVID-19; 6 days later, she presented abdominal pain located in the right hypochondrium and epigastrium, associated with emetic episodes. Re-consultation 21 days later due to the same symptoms; three days after the second dose of the vaccine was administered.Clinical FindingsPain on palpation in the right hypochondrium. Laboratories reported hepatocellular lesion and cholestasis, with negative amylase, hepatotropic virus and autoimmune hepatitis tests. Liver and biliary tract ultrasound and cholangioresonance were normal.Treatment And ResultsHyoscine and intravenous fluids as support therapy. She presented improvement in abdominal pain and progressive decrease of transaminases and bilirubin levels until normalization, and was discharged on the fifth day of hospitalization. A drug-associated hepatotoxicity (DILI) diagnosis was considered probable, in this case, secondary to vaccination against COVID-19.Clinical RelevanceThe current SARS CoV-2 pandemic has spurred the development of new vaccines, the safety of which remains a concern. There is a likely causal relationship between vaccination and liver involvement in this clinical case, rather than simply a sporadic occurrence.Copyright © 2022 Colombia Medica.

16 keywords...

hide…